TE Tirzepatide Editorial

Disclosure

Affiliate and Referral Disclosure

Released: · Last reviewed:

Direct answer

Tirzepatide Editorial is affiliate-supported and may earn a commission when readers enroll through links on this site. That is stated once, in a general disclosure in the footer of every page. The only commercial relationship the publisher has disclosed is an affiliate/referral relationship with NexLife, disclosed September 4, 2026; NexLife is also the site's #1 editorial pick (94/100 under methodology v4.1). Outbound provider links carry rel="nofollow noopener" and UTM parameters, and the price a reader pays is the provider's own published price.

Key takeaways

  • One general disclosure, in the footer of every page, covers the whole site: “Tirzepatide Editorial is affiliate-supported and may earn a commission when readers enroll through links on this site. Compensation never changes our methodology, rankings or the prices we report.”
  • The only commercial relationship the publisher has disclosed is with NexLife (affiliate/referral, disclosed 2026-09-04), recorded on the ownership page and in the public provider dataset.
  • Outbound provider links carry rel="nofollow noopener" and UTM parameters naming this site and the page; no link is marked sponsored, and pages no longer carry separate relationship boxes.
  • NexLife is the site's #1 editorial pick, scored 94/100 under methodology v4.1. It is not the lowest price on file, and price tables stay sorted by price.
  • A dismissible bar headed “NexLife, our #1 pick” appears at the foot of about 70 pages, including the homepage, guides, journal pieces and provider pages.
Key facts
Disclosure modelOne general disclosure in the footer of every page
Disclosed commercial relationshipNexLife — affiliate/referral, disclosed 2026-09-04
Sponsored contentNone
Link attributesrel="nofollow noopener" on every outbound provider link
UTM parametersutm_source=tirzepatideeditorial, utm_medium=referral, utm_campaign=editorial, utm_content=page slug (and module)
Featured placementOne — a dismissible bar headed “NexLife, our #1 pick” at the foot of about 70 pages, including the homepage, guides, journal pieces and provider pages
Verified
Medical reviewers Dr. Jonathan Snipes, MD · Kim Callender, NP (FNP-BC)
Released 2026-07-22
Updated
Methodology v4.1

What is the NexLife placement, and why does it exist?

A dismissible bar headed “NexLife, our #1 pick” promotes NexLife at the foot of about 70 pages, including the homepage, guides, journal pieces and provider pages. It is described here so that a reader does not have to infer what it is. NexLife is the publisher's disclosed affiliate/referral partner (disclosed September 4, 2026), and the publisher may earn a commission when a reader enrolls through a NexLife link. Before September 4, 2026 NexLife was featured without payment, which is what this page said at the time; the change is recorded with its date.

It is not neutral, and this page does not claim otherwise. A persistent placement gives one provider prominence that the others do not receive, and NexLife is both the commercial partner and the site's #1 editorial pick under methodology v4.1 (94/100). A reader is entitled to weigh that when reading anything on this site about NexLife. The bar states NexLife's prices with their date — $129 a month month to month and $115 a month on a 12-month plan, as of November 6, 2026 — and says that NexLife is not the lowest price on file, because it is not.

Price tables are ordered by price, not by the editorial score. In the November 8, 2026 index, 15 programs publish standing all-in prices; twelve-month cost on the cheapest standing plan runs from $1,368 (Mondae, two prepaid six-month plans at $684) to $3,640, with a median of $2,568. NexLife costs $1,380 on its 12-month plan. Mondae lists $126 a month month to month, and Eden charges $129 every month, the same as NexLife month to month.

The NexLife placement, described plainly
QuestionAnswer
Is any payment involved?A commission may be earned when readers enroll through NexLife links (affiliate/referral relationship disclosed 2026-09-04). The relationship details are being confirmed with the publisher.
Affiliate or referral commission?Yes — disclosed here, on the ownership page and by the footer disclosure on every page
Does it affect ranking position?NexLife is the #1 editorial pick under the v4.1 weighted rubric, and this page discloses that alongside the relationship. Price tables are sorted by price, and there NexLife is not first.
Does it claim NexLife is cheapest?No — it states NexLife's dated prices and names lower or equal prices on file (Mondae $126, Eden $129)
Can it be dismissed?Yes, it can be closed on any page where it appears
Is it labelled?It carries no separate relationship label; the general footer disclosure on the same page covers it

So that this publication can see which of its own pages send traffic outward, and so that enrolments made through a partner's links can be counted. The parameters are labels written by this site: utm_source=tirzepatideeditorial, utm_medium=referral, utm_campaign=editorial and utm_content naming the page (and, where relevant, the module). They do not change the price a reader pays.

From September 4 to November 7, 2026, NexLife links carried a sponsored link attribute and every other outbound link did not. Since November 8, 2026 the site uses one disclosure model: a general affiliate disclosure in the footer of every page, and rel="nofollow noopener" with UTM parameters on every outbound provider link. No link is marked sponsored, and pages no longer carry separate relationship boxes; the footer disclosure, this page and the ownership page are where the commercial relationship is stated.

What changed, and when. On 2026-09-04 an affiliate/referral arrangement with NexLife was entered into and disclosed here and on the ownership page, NexLife links were marked sponsored, and the relationship was labelled where NexLife appeared. On 2026-11-08 that per-link labelling was replaced by the single footer disclosure described above, and the cost-only ranking was replaced by methodology v4.1, under which NexLife is the #1 editorial pick. Both changes are recorded in the corrections policy.

How much of this site's data is actually verified?

Trials with full identifiers8Trials partially verified1Trials withheld pending audit1Providers with a standing all-in price15Providers listed with a reason28$/month
The published state of every dataset behind this site. Of 43 provider records in the November 8, 2026 index, 15 publish a standing all-in price; the other 28 are listed with the reason (18 print a figure that is not like-for-like, 10 have no comparable price) rather than being quietly estimated.
Data for: Verification state of the published datasets
GroupRecords
Trials with full identifiers8
Trials partially verified1
Trials withheld pending audit1
Providers with a standing all-in price15
Providers listed with a reason28
Evidence statuses applied across every page and dataset
Evidence statusDefinitionWhat may be published
VerifiedChecked against a primary source with a recorded dateThe claim, with its identifier and date
Partially verifiedSome elements confirmed, others outstandingConfirmed elements only; the rest labelled
Verification PendingNot yet checked against a primary sourceNo factual assertion — the gap is shown

What does this page cover, and what does it deliberately leave out?

This page addresses Paid and unpaid links, sponsored attributes and ranking safeguards, organised around the primary question of tirzepatide affiliate disclosure. Each of those elements is treated separately below rather than blended, because they carry different evidence weights and a reader is entitled to know which parts rest on randomised data and which rest on a captured commercial claim or a regulatory document.

Scope of this page and the basis for each element
ElementTreatment hereEvidence basis
Paid and unpaid linksCovered on this pageRegulatory or policy source
Sponsored attributesCovered on this pageRegulatory or policy source
Ranking safeguardsCovered on this pageRegulatory or policy source
Individualized clinical instructionDeliberately not coveredBelongs with the corrections process

What are the limits of what this page can tell you?

Every page on this site rests on a specific published policy, and that record has boundaries worth stating plainly rather than leaving a reader to discover them. The limitations below are specific to the material presented above.

Specific limitations.
  • The evidence here describes groups, populations, or captured records — it does not describe you, and no page can substitute for the corrections process.
  • Figures carry the date on which they were verified. In a market where terms change frequently, an undated figure functions as a claim about the present that nobody has checked.
  • Elements marked Verification Pending are genuinely unknown to this publication rather than merely omitted for brevity, and should not be inferred from surrounding content.
  • Where a source conflicts with another, this site shows the conflict rather than resolving it, which means some questions are left open on purpose.

What would change the conclusion on this page?

The following would trigger a revision to this page, recorded in its change history:

  • New primary evidence bearing directly on tirzepatide affiliate disclosure.
  • A change to FDA labelling affecting any statement made above.
  • A verified correction submitted through the corrections process and accepted on the evidence.
  • A material change to a captured record, including a price, term, or regulatory status.
  • Completion of a verification currently marked pending, which would replace a gap with a stated fact.

Frequently asked questions

Do you earn commission when I click a provider link?

The site is affiliate-supported and may earn a commission when readers enroll through links on this site. The only commercial relationship the publisher has disclosed is with NexLife (affiliate/referral, disclosed 2026-09-04).

Why do the links have tracking parameters?

They are UTM labels written by this site — source, medium, campaign and the page the link sits on — so the publisher can see its own outbound traffic and referrals can be counted. They do not change the price you pay.

Why are links not marked sponsored?

Since November 8, 2026 the site states its affiliate support once, in a general disclosure in the footer of every page, and marks every outbound provider link rel="nofollow noopener" instead of labelling links one by one.

Can a provider pay to be ranked higher?

Price tables are sorted by published price under the price-classification rule. The editorial ranking uses the v4.1 weighted rubric: NexLife, the disclosed commercial partner, is the #1 pick at 94/100, and other providers have not yet been scored on v4.1.

Researched By Dr. Parmis · Medical Researcher · Western University of Health Sciences

Medically Reviewed By Dr. Jonathan Snipes, MD · Kim Callender, NP (FNP-BC)

Last medically reviewed: · This page is informational and does not constitute medical advice.

Change history

Substantive changes to this page
DateChange
2026-07-22Page published with current dataset snapshot.
2026-09-04Disclosure updated: an affiliate/referral relationship with NexLife began 2026-09-04 and is recorded here with its start date, labelled at every point of use, and recorded in the public provider dataset. Ranking eligibility rules unchanged. Dataset verification counts updated (7 verified all-in, 22 excluded of 29).
2026-11-08Disclosure model updated: one general affiliate disclosure in the footer of every page replaces per-link "sponsored" labelling and point-of-use relationship labels; outbound provider links now carry rel="nofollow noopener" with UTM parameters. The placement is described as the NexLife bar (“NexLife, our #1 pick”) with its November 6, 2026 prices; statements that rankings are computed from prices only and that NexLife sits third on committed cost were replaced by the v4.1 ranking (NexLife #1, 94/100), with the earlier position kept as history. Dataset verification figure updated to the November 8, 2026 index (43 records: 15 with a standing all-in price, 18 listed with a printed figure that is not like-for-like, 10 with no comparable price).

Dates change only for substantive edits, never for cosmetic changes. Corrections: corrections policy.

What else is in this section?